Dholaria Hetal, Naranjo Arlene, Zhang Fan F, London Wendy B, Diller Lisa, Shamberger Robert C, Barnewolt Carol E, Schmidt Mary Lou, Maris John M, Cohn Sue L, Bagatell Rochelle, Nuchtern Jed G
Department of Oncology, Perth Children's Hospital, Perth, Australia.
WA Kids Cancer Center, The Kids Research Institute Australia, Perth, Australia.
Pediatr Blood Cancer. 2025 Aug;72(8):e31829. doi: 10.1002/pbc.31829. Epub 2025 Jun 1.
Several studies have established that patients with localized perinatal neuroblastoma can be safely observed; however, long-term outcomes have not been previously reported. We evaluated long-term outcomes of infants with suspected perinatal neuroblastoma enrolled on the Children's Oncology Group (COG) ANBL00P2, which included an expectant observation approach. Among 87 eligible patients, the 10-year event-free survival (EFS) was 93.7%, and overall survival (OS) was 98.0%. Most tumors regressed spontaneously; only three patients reported progression to higher stage disease. This report reinforces the long-term safety of non-interventional management in perinatal neuroblastoma, sparing infants unnecessary surgery and associated risks.
多项研究已证实，局限性围生期神经母细胞瘤患者可安全观察；然而，此前尚未报告长期预后情况。我们评估了参加儿童肿瘤协作组（COG）ANBL00P2研究的疑似围生期神经母细胞瘤婴儿的长期预后，该研究采用了观察等待的方法。在87例符合条件的患者中，10年无事件生存率（EFS）为93.7%，总生存率（OS）为98.0%。大多数肿瘤自发消退；只有3例患者病情进展至更高分期。本报告强化了围生期神经母细胞瘤非干预性管理的长期安全性，使婴儿避免了不必要的手术及相关风险。
